Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase IV transition to Raptiva in chronic plaque psoriasis
NL-OMON31969Phase 4Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of efalizumab in psoriasis (5 arms), sponsored by Merck & Co. Primary endpoint: Safety. Started Sep 2008; status: active, not recruiting.
02
Drugs
efalizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON31969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31969.